Lauren Dierdorff is an innovative scientist with expertise at the intersection of neuroscience and biotechnology, dedicated to leveraging scientific advancements to drive biotech innovation and transformative healthcare solutions.

 

Lauren is a Ph.D. candidate in Neuroscience at the Icahn School of Medicine at Mount Sinai, conducting translational research in the De Rubeis lab within the Seaver Autism Center for Research and Treatment and Department of Psychiatry. Her work focuses on the cortical circuits underlying motor deficits in a model of DDX3X syndrome, a rare genetic neurodevelopmental disorder. Since joining the lab in 2021, she has received recognitions including a National Institutes of Health (NIH) T32 traineeship (T32HD075735) and the Beatrice and Samuel A. Seaver Foundation Predoctoral Fellowship.

 

Beyond academia, Lauren contributes to the life sciences ecosystem through Nucleate, a nonprofit organization led by academic trainees. In 2024, she served as Education Director for Nucleate’s Business Development 101 (BD101) program in collaboration with Genentech, where she developed and delivered training on key biotech business development topics, including deal processes, asset evaluation, and market analysis. She also holds the role of Co-Director of Community and Events for Nucleate’s New York Chapter, fostering collaboration and professional development across the New York  biotech community.

 

At Atoll, Lauren applies her scientific and strategic expertise to conducting scientific due diligence and helping to build strong client relationships in the biotech and life sciences sectors.  Lauren’s multidisciplinary approach and dedication to driving innovation make her a valuable contributor to advancing healthcare through science and business collaboration.